MILWAUKEE, Oct. 30, 2025 /PRNewswire/ -- The Society for Immunotherapy of Cancer (SITC) received an incredible number of abstract submissions in 2025, more than 1,300, including many clinical based ...
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (ALXO),, an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today ...
PENNINGTON, N.J. and SAN DIEGO, May 21, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (the "Company" or "OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer ...
MARSEILLE, France--(BUSINESS WIRE)-- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today three abstracts including Innate’s product candidates have been ...
Real-world data from 844,000 patient records highlight the power of remote therapeutic monitoring to improve outcomes and reduce risk in chronic pain care The abstract presents a retrospective cohort ...
KRAKOW, Poland, May 12, 2021 /PRNewswire/ — Ryvu Therapeutics (WSE: RVU) today announced that three abstracts demonstrating clinical and pre-clinical activity of its selective CDK8/19 inhibitor RVU120 ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--H3 Biomedicine Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the presentation of four posters ...
Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting Oral presentation on SAR’579 / IPH6101, a potential first-in-class NKp46/CD16-based NK cell engager targeting CD123; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback